Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Elevated Lipoprotein(a) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

NCT01959971
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 23, 2026, 8:19 PM EDT
Recruiting Not applicable Interventional

Atlantic Lipid Lowering Treatment Optimization Program

NCT06439654
View directory record Official record
Conditions
Familial Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Apolipoprotein B 100, Familial Defective, High Density Lipoprotein Deficiency, Low-Density-Lipoid-Type Hyperlipoproteinemia
Interventions
Supportive care
Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Clark, New Jersey • Springfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

NCT02585895
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Biological · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism

NCT00327002
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
LY518674
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Sep 23, 2026, 8:19 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Interventions
Lepodisiran Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
17,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
222
States / cities
Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Trilipix Effects on Lipids and Arteries

NCT01025492
View directory record Official record
Conditions
Dyslipidemia
Interventions
Trilipix, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

NCT05563246
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
LY3473329, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Dorchester, Massachusetts • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 23, 2026, 8:19 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

NCT06597006
View directory record Official record
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

NCT00768274
View directory record Official record
Conditions
Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 23, 2026, 8:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lipid Screening Study

NCT07579325
View directory record Official record
Conditions
Lipoprotein (a)
Interventions
Venipuncture
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Active, not recruiting Phase 3 Interventional

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
7,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
133
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 112 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3015014 in Participants With High Cholesterol

NCT01890967
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LY3015014, Placebo, Statin, Ezetimibe
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Encino, California • Lancaster, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

NCT00697203
View directory record Official record
Conditions
Dyslipidemia
Interventions
Placebo, Pravastatin, Dalcetrapib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
33
States / cities
Mobile, Alabama • Scottsdale, Arizona • Newark, Delaware + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 23, 2026, 8:19 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation

NCT07626281
View directory record Official record
Conditions
Inclisiran Formulation
Interventions
Inclisiran formulation containing PS80, Currently marketed inclisiran formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

NCT02729025
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Miami, Florida • Las Vegas, Nevada • Mooresville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol

NCT00529542
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Lipitor, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 on Pharmacokinetics in Healthy Participants

NCT01448824
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2484595, Placebo, Ketoconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

NCT04270760
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Olpasiran, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Beverly Hills, California • Boca Raton, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Not applicable Interventional

Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome

NCT02542176
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Freeze-dried Whole Grape Powder, Grape Powder Placebo
Other
Lead sponsor
University of Connecticut
Other
Eligibility
30 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Not applicable Interventional

Effects of Lean Pork, High Protein Breakfast on Satiety and Metabolic Health in Pre-diabetes

NCT02934425
View directory record Official record
Conditions
Pre-diabetes
Interventions
Refined carbohydrate-rich breakfast, High pork protein breakfast
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 74 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 23, 2026, 8:19 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

NCT06980428
View directory record Official record
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

NCT04606602
View directory record Official record
Conditions
Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
Interventions
SLN360, Placebo
Drug
Lead sponsor
Silence Therapeutics plc
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Jacksonville, Florida • Port Orange, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 23, 2026, 8:19 PM EDT